Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 10/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 8/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anabasine SCHEMBL3465120 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL30835558 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL117530 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29634446 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL6801148 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL1004341 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL9673975 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29421176 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL9673965 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL7194509 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280404-A1 | Inhibitors of Glucose Kinases, Along with Methods of Their Formation and Use | UNIVERSITY OF SOUTH CAROLINA | 2018-10-04 | — | — | US | claimed |
| CN-110590644-B | Chiral 1, 2-dihydropyridine compound, preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-114732148-A | Application of anabasine in heating non-combustion electron delivery product, solid-state slice and preparation method thereof | 汪冶 | 2022-07-12 | — | — | CN | disclosed |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-06-16 | — | — | US | disclosed |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-06-16 | — | — | US | disclosed |
| US-10548895-B2 | Ligands that target Plasmodium sporozoite binding sites on CD81 and therapeutic methods using them | THE AMERICAN UNIVERSITY IN CAIRO (EG) | 2020-02-04 | — | — | US | disclosed |
| US-20180280404-A1 | Inhibitors of Glucose Kinases, Along with Methods of Their Formation and Use | UNIVERSITY OF SOUTH CAROLINA | 2018-10-04 | — | — | US | disclosed |
| US-20180280404-A1 | Inhibitors of Glucose Kinases, Along with Methods of Their Formation and Use | UNIVERSITY OF SOUTH CAROLINA | 2018-10-04 | — | — | US | disclosed |
| US-20170258792-A1 | LIGANDS THAT TARGET PLASMODIUM SPOROZOITE BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | American University In Cairo (AUC) (EG) | 2017-09-14 | — | — | US | disclosed |
| US-20170258792-A1 | LIGANDS THAT TARGET PLASMODIUM SPOROZOITE BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | American University In Cairo (AUC) (EG) | 2017-09-14 | — | — | US | disclosed |
| US-20170258792-A1 | LIGANDS THAT TARGET PLASMODIUM SPOROZOITE BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | American University In Cairo (AUC) (EG) | 2017-09-14 | — | — | US | disclosed |
| US-20150328329-A1 | LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | American University of Cairo (EG) | 2015-11-19 | — | — | US | disclosed |
| WO-2014081856-A2 | LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | AZZAZY HASSAN (EG) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280404-A1 | Inhibitors of Glucose Kinases, Along with Methods of Their Formation and Use | GCK, GCKR, GALK1 | CHRNB2 3000/4885CHRNA4 3242/4885CHRNA7 2740/4885 |
| US-20170258792-A1 | LIGANDS THAT TARGET PLASMODIUM SPOROZOITE BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM | CD81, HAVCR2, SELPLG | CHRNB2 3177/4885CHRNA4 3784/4885CHRNA7 4068/4885 |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | GCK, GCKR, GALK1 | CHRNB2 3000/4885CHRNA4 3242/4885CHRNA7 2740/4885 |
| US-10548895-B2 | Ligands that target Plasmodium sporozoite binding sites on CD81 and therapeutic methods using them | CD81, HAVCR2, SELPLG | CHRNB2 3177/4885CHRNA4 3784/4885CHRNA7 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.